Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 15/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11192313 | 0.82 | DPP4 (0.49) | DPP4 | |
| SCHEMBL6950828 | 0.79 | GAA (0.41) | DPP4DPP8DPP9 | |
| SCHEMBL11380419 | 0.77 | DPP4 (0.37) | DPP4DPP8DPP9 | |
| SCHEMBL11379024 | 0.76 | DPP4 (0.37) | DPP4DPP8DPP9 | |
| SCHEMBL11376697 | 0.76 | DPP4 (0.36) | DPP4DPP8DPP9 | |
| SCHEMBL11374506 | 0.76 | PREP (0.37) | DPP4DPP8DPP9 | |
| SCHEMBL11372100 | 0.75 | ALDH1A1 (0.39) | KMT2ADPP4DPP8DPP9 | |
| SCHEMBL11377773 | 0.75 | — | — | |
| SCHEMBL11386347 | 0.74 | PREP (0.36) | DPP4DPP8DPP9 | |
| Dimethylamine SCHEMBL11372839 | 0.73 | PREP (0.35) | DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027041-B1 | NOVEL CYANOAZIRIDINES FOR TREATING CANCER | AMPLIMED INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030129222-A1 | Administering to a cancer patient a therapeutically effective amount of imexon or derivative in combination with one or more lipids to treat the cancer | VALLEY VENTURES III, L.P. | 2003-07-10 | — | — | US | disclosed |
| US-6297230-B1 | N-CARBAMOYL-SUBSTITUTED | AMPLIMED, INC. | 2001-10-02 | — | — | US | disclosed |
| EP-1027041-A4 | NOVEL CYANOAZIRIDINES FOR TREATING CANCER | UNIV ARIZONA (US) | 2001-06-13 | — | — | EP | disclosed |
| EP-1027041-A1 | NOVEL CYANOAZIRIDINES FOR TREATING CANCER | THE ARIZONA BOARD OF REGENTS, ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999000120-A1 | NOVEL CYANOAZIRIDINES FOR TREATING CANCER | ARIZONA BOARD OF REGENTS, UNIVERSITY OF ARIZONA (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030129222-A1 | Administering to a cancer patient a therapeutically effective amount of imexon or derivative in combination with one or more lipids to treat the cancer | ABHD16A, PNLIP, LIPA | KMT2A 3657/4885DPP4 3112/4885MCL1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.